共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
4.
5.
New bismuth‐containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice 下载免费PDF全文
Antonio Tursi Francesco Di Mario Marilisa Franceschi Rudi De Bastiani Walter Elisei Gianluca Baldassarre Antonio Ferronato Simone Grillo Stefano Landi Maria Zamparella Manuela De Polo Laura Boscariolo Marcello Picchio 《Helicobacter》2017,22(3)
6.
7.
8.
Efficacy of three‐in‐one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population 下载免费PDF全文
Stephan Miehlke Dorothea Frederking Thomas Günther Erik Glocker Bianca Eisele Viola Andresen Sören Schröder Andrea Morgner 《Helicobacter》2017,22(6)
9.
10.
11.
12.
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton‐pump inhibitor,bismuth, amoxicillin,and metronidazole in Korea 下载免费PDF全文
Jung Wan Choe Sung Woo Jung Seung Young Kim Jong Jin Hyun Young Kul Jung Ja Seol Koo Hyung Joon Yim Sang Woo Lee 《Helicobacter》2018,23(2)
13.
14.
15.
16.
The “three‐in‐one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice 下载免费PDF全文
Rocco Maurizio Zagari Alessandra Romiti Enzo Ierardi Antonietta G. Gravina Alba Panarese Giuseppe Grande Edoardo Savarino Giovanni Maconi Elisa Stasi Leonardo Henry Eusebi Fabio Farinati Rita Conigliaro Franco Bazzoli Marco Romano 《Helicobacter》2018,23(4)
17.
18.
Helicobacter pylori (H. pylori) infection has been associated with gastric disorders. The situation of H. pylori infection in China—where a high prevalence of H. pylori infection, a high incidence of gastric cancer, and widespread resistance to clarithromycin, metronidazole, and levofloxacin exist—is quite different from that in Western countries. In order for Chinese clinicians to better manage H. pylori infection, a Chinese Study Group on H. pylori published four consensus reports regarding the management of H. pylori infection in China between 1999 and 2012. The eradication rate with standard triple therapy was <80% in most areas of China. Bismuth is available in China, and bismuth‐containing quadruple therapy has been shown to produce a high eradication rate; thus, bismuth quadruple therapy could be recommended both as an initial and as a rescue therapy in China. There is no advantage of sequential therapy over triple therapy in Chinese patients, but the efficacy of concomitant therapy must be studied further. This review introduces the epidemiology, diagnosis, indicators, and therapies for the eradication of H. pylori in China in recent years. 相似文献
19.
20.
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China 下载免费PDF全文
Yong Xie Zhenyu Zhang Junbo Hong Wenzhong Liu Hong Lu Yiqi Du Weihong Wang Jianming Xu Xuehong Wang Lijuan Huo Guiying Zhang Chunhui Lan Xiaoyan Li Yanqing Li Hong Wang Guoxin Zhang Yin Zhu Xu Shu Ye Chen Jiangbin Wang Nonghua Lu the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori 《Helicobacter》2018,23(5)